Cargando…

Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial

INTRODUCTION: Primary open angle glaucoma is an insidious and chronic vision-threatening eye ailment due to neuro-retino-optic nerve degeneration, which may be due to the raised intraocular pressure (IOP) or due to independent factors. Management of glaucoma is mainly concentrated on lowering IOP th...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhiman, K. S., Adhoor, Veeranagouda S., Agarwal, Riju, Mehta, Amit J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688835/
https://www.ncbi.nlm.nih.gov/pubmed/29200751
http://dx.doi.org/10.4103/ayu.AYU_30_16
_version_ 1783279252128399360
author Dhiman, K. S.
Adhoor, Veeranagouda S.
Agarwal, Riju
Mehta, Amit J.
author_facet Dhiman, K. S.
Adhoor, Veeranagouda S.
Agarwal, Riju
Mehta, Amit J.
author_sort Dhiman, K. S.
collection PubMed
description INTRODUCTION: Primary open angle glaucoma is an insidious and chronic vision-threatening eye ailment due to neuro-retino-optic nerve degeneration, which may be due to the raised intraocular pressure (IOP) or due to independent factors. Management of glaucoma is mainly concentrated on lowering IOP that requires lifetime topical medication, different ocular medicaments for lowering of IOP, and surgical interventions, but it has its own limitations to control the progression of glaucomatous optic neuropathy (GON), and this is the reason behind the use of alternative neuroprotective adjuvants. AIM: To evaluate the neuroprotective effect of Ayurvedic line of management of progressive GON. MATERIALS AND METHODS: Ingredients of trial drug Vara Fort powder (Chakshushya Rasayana) were procured from the Institute Pharmacy, except Swarnamakshika Bhasma, which was purchased from Dhootapapeshwar Pharmaceuticals. The patients fulfilling inclusion criteria, attending outpatient and inpatient departments, irrespective of their sex, race, religion, occupation, etc., were selected and divided into two groups with open-labeled randomization. In Group A, in addition to betaxolol (0.1%) or timolol (0.5%) (non-iobrim), Chakshushya Rasayana 6 g/day orally with Triphala Ghrita and honey along with Koshtha-Shuddhi (body-microchannel clearing treatment) protocol was tried. Nasya (oleation through nasal route) with Jeevantyadi Taila and Tarpana (eye satiation) with Go-Ghrita were also performed. In Group B (control), brimonidine (iobrim) 0.2% eye drop was used for 3 months. RESULTS: Significant improvement was observed in subjective parameters in Group A such as blurred vision, frequent change of presbyopic glasses, and delayed dark adaptation. CONCLUSION: Chakshushya Rasayana, if administered in a systematic approach along with a modern topical betaxolol or timolol eye drops, has a definite role in improving the lost retinal sensitivity as much as up to 12 dB in 3 months duration.
format Online
Article
Text
id pubmed-5688835
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-56888352017-12-01 Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial Dhiman, K. S. Adhoor, Veeranagouda S. Agarwal, Riju Mehta, Amit J. Ayu Original Article INTRODUCTION: Primary open angle glaucoma is an insidious and chronic vision-threatening eye ailment due to neuro-retino-optic nerve degeneration, which may be due to the raised intraocular pressure (IOP) or due to independent factors. Management of glaucoma is mainly concentrated on lowering IOP that requires lifetime topical medication, different ocular medicaments for lowering of IOP, and surgical interventions, but it has its own limitations to control the progression of glaucomatous optic neuropathy (GON), and this is the reason behind the use of alternative neuroprotective adjuvants. AIM: To evaluate the neuroprotective effect of Ayurvedic line of management of progressive GON. MATERIALS AND METHODS: Ingredients of trial drug Vara Fort powder (Chakshushya Rasayana) were procured from the Institute Pharmacy, except Swarnamakshika Bhasma, which was purchased from Dhootapapeshwar Pharmaceuticals. The patients fulfilling inclusion criteria, attending outpatient and inpatient departments, irrespective of their sex, race, religion, occupation, etc., were selected and divided into two groups with open-labeled randomization. In Group A, in addition to betaxolol (0.1%) or timolol (0.5%) (non-iobrim), Chakshushya Rasayana 6 g/day orally with Triphala Ghrita and honey along with Koshtha-Shuddhi (body-microchannel clearing treatment) protocol was tried. Nasya (oleation through nasal route) with Jeevantyadi Taila and Tarpana (eye satiation) with Go-Ghrita were also performed. In Group B (control), brimonidine (iobrim) 0.2% eye drop was used for 3 months. RESULTS: Significant improvement was observed in subjective parameters in Group A such as blurred vision, frequent change of presbyopic glasses, and delayed dark adaptation. CONCLUSION: Chakshushya Rasayana, if administered in a systematic approach along with a modern topical betaxolol or timolol eye drops, has a definite role in improving the lost retinal sensitivity as much as up to 12 dB in 3 months duration. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5688835/ /pubmed/29200751 http://dx.doi.org/10.4103/ayu.AYU_30_16 Text en Copyright: © 2017 AYU (An International Quarterly Journal of Research in Ayurveda) http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Dhiman, K. S.
Adhoor, Veeranagouda S.
Agarwal, Riju
Mehta, Amit J.
Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial
title Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial
title_full Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial
title_fullStr Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial
title_full_unstemmed Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial
title_short Adjuvant effect of Chakshushya Rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: An open-label randomized controlled trial
title_sort adjuvant effect of chakshushya rasayana with beta-blocker eye drops in the management of progressive glaucomatous optic neuropathy: an open-label randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688835/
https://www.ncbi.nlm.nih.gov/pubmed/29200751
http://dx.doi.org/10.4103/ayu.AYU_30_16
work_keys_str_mv AT dhimanks adjuvanteffectofchakshushyarasayanawithbetablockereyedropsinthemanagementofprogressiveglaucomatousopticneuropathyanopenlabelrandomizedcontrolledtrial
AT adhoorveeranagoudas adjuvanteffectofchakshushyarasayanawithbetablockereyedropsinthemanagementofprogressiveglaucomatousopticneuropathyanopenlabelrandomizedcontrolledtrial
AT agarwalriju adjuvanteffectofchakshushyarasayanawithbetablockereyedropsinthemanagementofprogressiveglaucomatousopticneuropathyanopenlabelrandomizedcontrolledtrial
AT mehtaamitj adjuvanteffectofchakshushyarasayanawithbetablockereyedropsinthemanagementofprogressiveglaucomatousopticneuropathyanopenlabelrandomizedcontrolledtrial